New surgical robot is safe and effective for localized prostate cancer surgery
Newswise—May 182022 – New surgical robotic system is ‘feasible, safe and effective’ for treating early-stage prostate cancerconcludes a first evaluation in The Journal of Urology®an official journal of the American Urological Association (AUA). The journal is published in the Lippincott Portfolio by Wolters Kluwer.
The new system, called KangDuo Surgical Robot-01, offers high precision and surgical success with low complication rates and a high level of surgeon comfort – and may provide a lower-cost alternative to current surgical robots. The study was led by Cheng Shen, Xuesong Li and Liquin Zhou from the Urology Department of Peking University First Hospital; Institute of Urology, Peking University; and National Urological Cancer Center, Beijing.
Initial experience in 16 patients with localized prostate cancer
The researchers analyzed their experience using the KangDuo system to perform robot-assisted radical prostatectomy (RARP) in 16 men with localized prostate cancer. Robot-assisted surgery for prostate cancer using the revolutionary da Vinci System has been available for two decades, with demonstrated advantages over conventional open or laparoscopic surgery.
“However, the costs of robotic surgery remain a concern and limit its use,” the researchers write. Developed in China, the KangDuo system has shown promising results in other types of operations.
The patients, with a median age of 66, had localized cancers that had not spread beyond the prostate. All procedures were performed by Professor Shen, who previously had extensive experience in prostatectomy using the da Vinci surgical robot. As his experience progressed, the median time the surgeon spent behind the KangDuo robotic system console went from 102 minutes for the first four cases to 75 minutes for the last four.
“These initial results showed that the [KangDuo] system is feasible, safe and effective for the management of localized prostate cancer,” the researchers write. All procedures were performed successfully with no major issues requiring conversion to traditional open surgery. suggesting that the cancer was completely removed by surgery.
There were no serious complications and no need for blood transfusions. Urinary incontinence is a potential complication after prostate cancer. In the new study, the continence rate was 87.5% (14 out of 16 patients) one month after catheter removal.
The KangDuo robotic system incorporates several important features to optimize hand-eye coordination and enable normal and adjustable neck posture. During the ergonomic assessment, the surgeon reported a “high level of comfort” using the robotic surgeon, with “acceptable” levels of mental and physical demands.
The initial experience revealed some minor technical issues – for example, the KangDuo system introduces a foot-operated clutch, which required additional training time for surgeons accustomed to the manual clutch of the da Vinci robotic system. Other improvements are planned, including a tactile feedback system and the ability to perform long-distance operations using 5G technology.
The researchers stress the importance of the continuous development of new robotic surgery platforms. “The da Vinci robotic system has dominated the robotic surgery market for a relatively long time, as the development of technology calls for diversification with more innovation,” the researchers write. The estimated costs for research, development and manufacturing are about 25-30% of those of the da Vinci system.
Approval of the KangDuo system is expected soon, first in the Chinese market and globally shortly thereafter. “Although the price has not yet been determined, the emergence of new robotic surgery systems is reducing the cost of robotic surgery, which could benefit more patients,” add Professor Shen and his co-authors. They point to the need for further study, including longer follow-up and comparison with the RARP performed using the da Vinci system.
On The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and cited journal in the field, The Journal of Urology® provides robust coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal features investigative studies on critical areas of research and practice, investigative articles providing brief editorial commentary on the best and most important literature in urology worldwide, and reports focused on practice on important clinical observations. The Journal of Urology® covers the broad spectrum of urology including pediatric urology, urological cancers, kidney transplantation, male infertility, urinary stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is one of the leading advocates for the specialty of urology and has nearly 24,000 members worldwide. The AAU is a leading urological association, providing invaluable support to the urological community in pursuit of its mission to foster the highest standards of urological care through education, research and formulation of health care policy. health. To learn more about the AAU, visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions and services for clinicians, nurses, accountants, lawyers and the tax, finance, auditing, risk, compliance and regulation. We help our customers make critical decisions every day by delivering expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer had annual sales of €4.6 billion in 2019. The group serves customers in over 180 countries, maintains operations in over 40 countries and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning, research and clinical intelligence. For more information on our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.